UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

~~February 4~~July 12, 2021

Date of Report (Date of earliest event reported)

EVIO, Inc. (Exact name of registrant as specified in its charter)

(Exact name of registrant as specified in its charter)

Colorado

000-12350

47-1890509

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2654 W. Horizon Ridge Parkway, Ste B5-208

Henderson, NV

89052

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code (702) 748-9944

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[☐ ] Written communications pursuant to Rule 425 under Securities Act (17 CFR 230.425) [☐ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [☐ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [☐ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ~~[X]~~☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1 8.01 ~~Entry~~Other ~~into a Material Definitive Agreement.~~Events

On ~~February~~ 4July 12, 2021, EVIO, Inc. ~~(the~~announced ~~“Company”)~~that it entered into ana 8%Letter ~~convertible~~of ~~promissory~~Intent ~~note~~to ~~(the~~acquire Leading Edge Pharms, Inc. (“~~Note~~LEP”) ~~with~~ ~~existing~~of ~~note~~Henderson, ~~holder~~Nevada, inpending ~~the~~shareholder ~~amount~~approval. ofLEP ~~$174,445.~~is ~~The~~a biotechnology company ~~received~~focused ~~$150,000~~on of the ~~proceeds~~research, ~~with~~development ~~$7,000~~and ~~allocated~~commercialization toof ~~legal expenses,~~novel ~~and~~cannabinoid antherapies ~~original~~and ~~issue~~innovative ~~discount~~drug ofdelivery ~~$17,445~~systems.

~~The note~~Terms ~~maybe~~of ~~prepaid~~the ~~based~~acquisition oninclude EVIO to perform detailed due diligence including technical review and testing of the ~~following~~company’s ~~schedule:~~products and methods. Closing of the transaction will be subject to; shareholder approval, authorization of additional shares to support the acquisition, EVIO will add at least two board members from LEP, and EVIO will release its audited financials. Upon completion of the deal, LEP will fill certain executive roles of the company.

Days Since Effective Date		Prepayment Amount
0-90		125% of Principal Amount
91-180		135% of Principal Amount
181+		150% of Principal Amount

Item 9.01 Financial Statements and Exhibits

~~At any~~Exhibit ~~time~~10.1 ~~after~~Press ~~the~~Release ~~Original~~- ~~Issue Date until the Note is no longer outstanding~~EVIO, ~~the~~Inc. ~~Note~~Enters ~~shall~~into beLetter ~~convertible at the lower~~ of ~~$0.006~~ orIntent ~~70%~~to ofAcquire ~~the~~Leading ~~lowest~~Edge ~~daily~~Pharms, ~~trade price in the twenty (20) Trading Days prior to the Conversion Date~~Inc.

The company has also entered into agreements with debenture holders from the January 29, 2018, October 17, 2018 and October 23, 2018 funding events to modify the terms of their debentures. The terms of the amendment, extend the maturity of these debentures to December 31, 2021 and modify the conversion price to $0.003. As of February 4, approximately $4.25 million of the outstanding $5.183 million have accepted the terms of the amendment.2

~~Item 2.03. Creation of a Direct Financial Obligation under an Off-Balance Sheet Arrangement of a Registrant.~~ SIGNATURES

~~See Item~~Pursuant ~~1.01~~to ~~above~~the ~~which~~requirements isof ~~incorporated~~the ~~herein~~Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by ~~reference~~the undersigned hereunto duly authorized.

Item 3.02 Unregistered Sales of Equity Securities.

	EVIO, INC.

Date: July 15, 2021	By:	/s/ Lori Glauser
		Lori Glauser
		Chief Executive Officer

~~The information set forth under Item 1.01 is incorporated herein by reference.~~3

Item 7.01 Regulation FD Disclosure.

The terms of this note specific that the proceeds from this Note must be used to facilitate the payment and completion of the company’s 10K report for the period ending September 30, 2020, and the company’s 8K report for the period ending December 31, 2020. The net proceeds have been distributed to the auditors, transfer agent, accountant and attorneys supporting the completion of these required reports.

Forward-Looking Statements

Statements contained in this current report that are not statements of historical fact are intended to be and are hereby identified as “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Generally, forward-looking statements include expressed expectations of future events and the assumptions on which the expressed expectations are based. All forward-looking statements are inherently uncertain as they are based on various expectations and assumptions concerning future events and they are subject to numerous known and unknown risks and uncertainties which could cause actual events or results to differ materially from those projected. The Company undertakes no obligation to update or revise this current report to reflect future developments except as otherwise required by the Securities Exchange Act of 1934.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EVIO, INC.,
Date: February 8, 2021	By:	/s/ Lori Glauser
		Lori Glauser
		Interim Chief Executive Officer

Filing Compare · EVIO, INC.